GLP-1 Market
LLY $1138.28 ▲ +2.0% NVO $43.45 ▲ +0.9% PFE $27.72 • 0.0% VKTX $31.53 ▼ -1.4% KLRA $13.75 ▼ -1.4% GPCR $38.44 ▼ -0.6% RHHBY $54.80 ▲ +3.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

UBT251 group

UBT251 group

Company
The United Bio-Technology (Hengqin) Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Injectable
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 15, 2026

Find a Clinical Trial Near Me

See recruiting studies for UBT251 group and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07653477

    Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)

    Not yet reported The United Bio-Technology (Hengqin) Co., Ltd. 956 participants Est. completion 2028-02-29 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: UBT251 group, UBT251 Injection 2.0 mg group, UBT251 Injection 4.0 mg group, UBT251 Injection 6.0 mg group

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.